Last reviewed · How we verify
Clofarabine VP 16 ciclophospahamide
Clofarabine VP 16 and cyclophosphamide work by interfering with DNA synthesis and function, leading to cell death in rapidly dividing cancer cells.
Clofarabine VP 16 and cyclophosphamide work by interfering with DNA synthesis and function, leading to cell death in rapidly dividing cancer cells. Used for Acute lymphoblastic leukemia.
At a glance
| Generic name | Clofarabine VP 16 ciclophospahamide |
|---|---|
| Also known as | Evoltra, Etoposide, Endoxan |
| Sponsor | Istituto Giannina Gaslini |
| Drug class | Nucleoside analog and alkylating agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Clofarabine VP 16 is a nucleoside analog that inhibits DNA polymerase and ribonucleotide reductase, while cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. This combination therapy is used to treat various types of cancer.
Approved indications
- Acute lymphoblastic leukemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clofarabine VP 16 ciclophospahamide CI brief — competitive landscape report
- Clofarabine VP 16 ciclophospahamide updates RSS · CI watch RSS
- Istituto Giannina Gaslini portfolio CI